Inspire Rally Recovers Lost Ground but Reimbursement and GLP-1 Risks Linger

What happened

Inspire Medical Systems shares surged 47.8% over three months, driven by improved Medicare reimbursement clarity, a quarterly earnings beat, $30 million in annual cost savings, and new CPT codes that solidify procedure economics. While these catalysts address near-term execution and margin concerns, the rally likely reflects a rebound from a deeply depressed base after a prolonged selloff that had priced in significant GLP-1 competition and DOJ scrutiny. The $30 million savings is modest relative to an $800 million revenue base, and the earnings beat may have relied on cost discipline rather than durable volume growth. New CPT codes reduce administrative friction but do not eliminate the risk that GLP-1 therapies divert eligible patients or that payers adjust coverage. Investors should treat the rally as a relief bounce rather than a fundamental re-rating until procedure volumes show sustained acceleration.

Implication

For risk-tolerant investors, the reimbursement and cost-savings confirmations strengthen the medium-term earnings power, but the 47.8% gain in three months likely leaves limited upside relative to the base-case value of $120 and increases downside if GLP-1 adoption accelerates. The rally may reflect a short squeeze or momentum trading as much as fundamentals, given the stock's history of extreme volatility and thinner institutional sponsorship. Near-term, investors should monitor whether procedure volumes re-accelerate and whether gross margins sustain above 86% as reimbursement flows through; without volume growth, the rally will fade. The DOJ investigation remains an overhang that could still introduce negative headlines, especially if marketing practices are questioned. A disciplined approach would wait for a pullback toward $90–$100, or a confirmed return to double-digit procedure growth, before adding, while those already holding may use strength above $130 to reduce risk.

Thesis delta

The prior thesis saw a potential buy at $99 with an attractive entry near $90 and trim above $135, predicated on reimbursement uplift, cost discipline, and Inspire V execution. The news confirms the reimbursement step-up and cost savings, increasing confidence in normalized EPS above $2 by 2026, but the sharp rally likely consumes much of the upside, pushing the stock closer to the upper end of the valuation range. The thesis now requires either a pullback to restore margin of safety or evidence of volume re-acceleration to justify paying up; otherwise, the risk/reward has shifted from moderately attractive to neutral.